WATERTOWN, Mass.--(BUSINESS WIRE)--Aug. 20, 2025-- Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, announced today that it has filed suit in the Unified Patent Court (UPC) of the European Union against Pfizer Inc. and certain of its subsidiaries (action number 35071/2025), seeking a determination of liability for use and infringement of European Patent No. EP 4 0

CRANBURY, N.J.--(BUSINESS WIRE)--Aug. 20, 2025-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Company’s pivotal Phase 2 trial of RP-A501 for the treatment of Danon disease. The hold was lifted in under three months, underscoring the efficiency of the

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 20, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces the completion of patient enrollment of SANOVO, a China Phase III study of ORPATHYS® (savolitinib) and TAGRISSO® (osimertinib) as a first-line treatment in certain non-small cell lung cancer (“NSCLC”) patients whose tumors harbor epidermal growth factor receptor (“EGFR”) mutation and MET overexpression. The last patient was enrolled

Saniona to receive US $42.5 million upfront; potential for development, regulatory and sales milestone payments in addition to royalties on future net sales Jazz obtains exclusive worldwide rights to develop and commercialize preclinical asset SAN2355 in epilepsy and other potential indications For U.S. media and investors only DUBLIN and COPENHAGEN, Denmark , Aug. 20, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Saniona (Nasdaq OMX: SANION) today announce that the companies

Investigating Its Role as an Immune Adjuvant in Cancer Immunotherapy TOKYO, Aug. 19, 2025 /PRNewswire/ -- ARC Therapies Inc. (Head Office: Shinjuku, Tokyo; President & CEO: Rami Suzuki), a certified startup from the National Cancer Center Japan, has initiated research of YB328, a newly identified gut microbe, toward clinical application. Utilizing its proprietary intellectual property, the company has designated the YB328 strain as ARC0812 (RUX: "Lux") and will proceed with preclinical and human

Guideline Emphasis on Earlier Treatment to Reduce Health, Dementia Risks Boosts Urgency to Keep Closer Watch on Blood Pressure OMRON innovations support 2025 guidelines on heart-brain connection, close blood pressure management throughout pregnancy, and healthy lifestyle behaviors HOFFMAN ESTATES, Ill., Aug. 19, 2025 /PRNewswire/ -- Heart health leader OMRON Healthcare today issued a national call-to-action for regular at-home blood pressure monitoring in response to new guidelines by the Ameri

JUPITER, Fla., Aug. 19, 2025 /PRNewswire/ -- Myosin Therapeutics, a biotechnology company developing novel therapies for aggressive cancers, today announced it has been awarded a $4.5M Phase IIB Bridge Award from the National Cancer Institute's (NCI) Small Business Innovation Research (SBIR) program. The funding will support Myosin Therapeutic's Phase I STAR-GBM dose escalation and expansion trial of MT-125, a first-in-class novel small molecule therapeutic being evaluated in patients with newly

Biolabs' CONNECTED DIAGNOSTICS App and decentralized clinical trial platform integrates rapid diagnostic testing, artificial intelligence, and telehealth, all accessible from a smartphone SAN DIEGO, Aug. 19, 2025 /PRNewswire/ -- Biolabs International LLC, a healthcare innovation company based in San Diego, California, is transforming how diagnostics are delivered and accessed , both in the home and in clinical research. Through the rollout of its CONNECTED DIAGNOSTICS App and decentralized clini

PITTSBURGH, Aug. 19, 2025 /PRNewswire/ -- "In 1986, while attending Smithsonian institute in Parkhill Denver, CO, I succeeded most recreational events through fasting and utilizing import herbs known to thrive in the USA," said an inventor, from Lakewood, Colo. "The non-narcotic organic imports contained (API) which aided in remedying azmatic refluxes, until the symptoms had dissolved. Later I was able to develop a patent for the Marquis Applications; which is a compound penicillin-type solid po

BeginNGS to partner with the Qatari Project NOOR to screen newborns for more than one thousand treatable genetic disorders DOHA, Qatar, Aug. 19, 2025 /PRNewswire/ -- Rady Children's Institute for Genomic Medicine (RCIGM®) today announced an agreement with Sidra Medicine, a world-class specialty healthcare organization for women, children and young people in the State of Qatar, to collaborate on implementing RCIGM's genome-based newborn screening program, BeginNGS (pronounced "beginnings"). Sidra